Bosulif bosutinib: Phase III started

In July, Avillion began the open-label, international Phase III BFORE trial to compare 400 mg oral Bosulif once daily vs. 400 mg oral imatinib once daily in about 530 newly diagnosed patients. In January, Avillion partnered with Pfizer to conduct an international Phase III trial of Bosulif as first-line treatment of chronic Ph+ CML. Avillion is funding and conducting the trial. If Bosulif is approved for the indication, Avillion would be eligible for undisclosed milestones. ...